Loading provider…
Loading provider…
Hematology & Oncology Physician in Salt Lake City, UT
NPI: 1023276490Primary Practice Location
UNIVERSITY OF UTAH HOSPITAL AND CLINICS
1950 Circle Of Hope Dr, Salt Lake City, UT
Primary Employer
VA Health Care System, Salt Lake City, UT
va.gov
HQ Phone
Get MD, MBA, FACP Shiven's Phone Numberphone_androidMobile
Get MD, MBA, FACP Shiven's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardUT State Medical License

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 79 | 253 |
| 2 | G2212Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 18 | 99 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 14 | 18 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 14 | 14 |
| 5 | 99214Established patient office or other outpatient visit, 30-39 minutes | 12 | 12 |
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.
Authors: Wajih Kidwai, Daniel Landsburg, Ashley Hicks, Peter Curtin, Rachel Rosovsky, Ivana Gojo, Sumithira Vasu, Raajit Rampal, Avyakta Kallam, Eric Kraut, Peter Westervelt, Gary Lyman
Journal: J Natl Compr Canc Netw
Lead Sponsor: NRG Oncology
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Docetaxel, DRUG: Pembrolizumab, DRUG: Gemcitabine, DRUG: Pemetrexed Disodium, DRUG: Erlotinib Hydrochloride, RADIATION: Stereotactic Body Radiation Therapy (SBRT), RADIATION: Intensity-Modulated Radiation Therapy (IMRT), RADIATION: 3-Dimensional Conformal Radiation Therapy (3D-CRT)
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Questionnaire Administration, OTHER: Fludeoxyglucose F-18, PROCEDURE: Positron Emission Tomography, PROCEDURE: Biospecimen Collection, OTHER: Quality-of-Life Assessment, DRUG: Atezolizumab, PROCEDURE: Computed Tomography, RADIATION: Stereotactic Body Radiation Therapy
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: NRG Oncology
Intervention / Treatment: DRUG: Carboplatin, OTHER: Questionnaire Administration, PROCEDURE: Biospecimen Collection, DRUG: Cisplatin, OTHER: Quality-of-Life Assessment, DRUG: Atezolizumab, RADIATION: Intensity-Modulated Radiation Therapy, DRUG: Etoposide, RADIATION: 3-Dimensional Conformal Radiation Therapy